Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.
The company reported that its genome-wide methylation approach could detect 77 percent of stage II cancers in its ongoing case-control CCGA study.
Thrive Earlier Detection is banking on targeted detection of frequent cancer mutations, coupled with protein markers, while competitors turn to genome-wide approaches.
The company is commercializing a method developed by researchers at Johns Hopkins that detects cancer with high specificity from a blood sample.
Novartis' alpelisib is the first PI3K inhibitor approved for advanced or metastatic breast cancer patients who harbor PIK3CA mutations.
The company said adopters are ordering tests in areas of great interest, like CTC and blood biomarker monitoring, despite a lack of reimbursement.
The group will define and quantify Stroma Liquid Biopsy biomarkers in Leiden University-collected sera to correlate them with Leiden's tumor-stroma ratio scoring methods.
The firm launched a study this year to validate the new CRC-specific immune-transcriptomic assay, aiming to obtain regulatory approval in Europe.
The test will guide clinical decision making related to Inovio's DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus.
The firm hopes for a decision from the FDA later this year for its breast cancer drug candidate alpelisib, following results from a late-stage trial.
The method's developers believe that clinicians could use approach to predict how high-grade, serous ovarian cancer patients will respond to chemotherapy.
During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
Take2 Health plans to launch an nasopharyngeal carcinoma early detection test in the next several months in Hong Kong and southern China.
The company's total revenue for the three months ended March 31 was $108.8 million compared to $92.6 million in the first quarter of 2018, exceeding analyst expectations.
Take2 was founded by Chinese University of Hong Kong researchers and will commercialize a cell-free DNA test for early cancer detection.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.
Investigators from a variety of clinical sites found that the company's liquid biopsy test was more successful in finding actionable mutations in patients than tumor tissue.
Concordance numbers and early evidence of clinical impact from a 100-patient first phase were sufficient to expand to another 450 individuals.